✦ LIBER ✦

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

✍ Scribed by Johan Hansson; Steinar Aamdal; Lars Bastholt; Yvonne Brandberg; Micaela Hernberg; Bo Nilsson; Ulrika Stierner; Hans von der Maase

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Health-related quality of life in patien

✍ Y. Brandberg; S. Aamdal; L. Bastholt; M. Hernberg; U. Stierner; H. von der Maase 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 419 KB

4LB Results of the Nordic randomised adj

✍ J. Hansson; S. Aamdal; L. Bastholt; M. Hernberg; B. Nilsson; U. Stierner; H. von 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 37 KB

Post-surgery adjuvant therapy with inter

✍ Alexander MM Eggermont; Stefan Suciu; Rona MacKie; Wlodzimierz Ruka; Alessandro 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 126 KB

Adjuvant therapy with pegylated interfer

✍ Alexander MM Eggermont; Stefan Suciu; Mario Santinami; Alessandro Testori; Wim H 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 236 KB

A randomised phase II trial of 1 mo

✍ Lili Mao; Lu Si; Zhihong Chi; Chuanliang Cui; Xinan Sheng; Siming Li; Bixia Tang 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 305 KB

Adjuvant therapy with pegylated interfer

✍ Jean Jacques Grob; Thomas Jouary; Brigitte Dréno; Julien Asselineau; Ralf Gutzme 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 406 KB